The quality markers of GR in the treatment of brain diseases after processing have been preliminarily identified to include gastrodin, S-(4-hydroxybenzyl)-glutathione, and the parishins B, C, and E. These markers may exhibit therapeutic effects against AD, MDD, and CI by acting on the pathways involving AKT1, SRC, MAPK, and other proteins. Here, AKT1 is linked to Alzheimer disease.